Evidence map›Paper›PMID 31785153›Full record

ArticleEuropean journal of immunology2020

Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.

Connie B Gilfillan, Chensu Wang, Mona O Mohsen, Nathalie Rufer, Michael Hebeisen, Mathilde Allard, Grégory Verdeil, Darrell J Irvine, Martin F Bachmann, Daniel E Speiser

Open access · hybridAbstract read
In one paragraph

Article in European journal of immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Connie B GilfillanDepartment of Oncology, University of Lausanne, Switzerland.ORCID 0000-0002-5574-1143
Chensu WangKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Mona O MohsenInselspital, Universitaetsklinik RIA, Immunologie, Bern, Switzerland.
Nathalie RuferDepartment of Oncology, University of Lausanne, Switzerland.
Michael HebeisenDepartment of Oncology, University of Lausanne, Switzerland.
Mathilde AllardDepartment of Oncology, University of Lausanne, Switzerland.
Grégory VerdeilDepartment of Oncology, University of Lausanne, Switzerland.ORCID 0000-0001-9445-8474
Darrell J IrvineKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.
Martin F BachmannInselspital, Universitaetsklinik RIA, Immunologie, Bern, Switzerland.
Daniel E SpeiserDepartment of Oncology, University of Lausanne, Switzerland.ORCID 0000-0003-2031-3250
University of Lausanne · CHKoch Institute for Integrative Cancer Research At MIT · USUniversity Hospital of Bern · CH

Funding

Lymph node-targeted molecular vaccinesR01EB022433 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IRVINE, DARRELL J · 2016 to 2019
$1.4M
Alfred and Annemarie von SickCancer Research InstituteLudwig Institute for Cancer ResearchNIBIB NIH HHS R01 EB022433Swiss Cancer Research 3971-08-2016Swiss Cancer Research 4291-08-2017The Swiss National Science Foundation 310030-179459Université de Lausanne
6 · The paper itself

Abstract

It is known that for achieving high affinity antibody responses, vaccines must be optimized for antigen dose/density, and the prime/boost interval should be at least 4 weeks. Similar knowledge is lacking for generating high avidity T-cell responses. The functional avidity (FA) of T cells, describing responsiveness to peptide, is associated with the quality of effector function and the protective capacity in vivo. Despite its importance, the FA is rarely determined in T-cell vaccination studies. We addressed the question whether different time intervals for short-term homologous vaccinations impact the FA of CD8 T-cell responses. Four-week instead of 2-week intervals between priming and boosting with potent subunit vaccines in C57BL/6 mice did not improve FA. Equally, similar FA was observed after vaccination with virus-like particles displaying low versus high antigen densities. Interestingly, FA was stable in vivo but not in vitro, depending on the antigen dose and the time interval since T-cell activation, as observed in murine monoclonal T cells. Our findings suggest dynamic in vivo modulation for equal FA. We conclude that low antigen density vaccines or a minimal 4-week prime/boost interval are not crucial for the T-cell's FA, in contrast to antibody responses.

Indexed as

AnimalsAntibody FormationAntigen PresentationAntigensCD8-Positive T-LymphocytesCells, CulturedImmunization, SecondaryMiceMice, Inbred C57BLPeptidesProtein BindingReceptors, Antigen, T-CellVaccinationVaccines, SubunitVaccines, Virus-Like ParticleAntigensPeptidesReceptors, Antigen, T-CellVaccines, SubunitVaccines, Virus-Like ParticleAvidity regulationFunctional avidityPrime/boostT-cell receptor affinityT-cell vaccination

Identifiers

PMID31785153
PMCPMC7187562
OpenAlexW2989811687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.